Related Experiment Video
Updated: Jul 3, 2026
06:04
Surgical Treatment for Benign Prostatic Hyperplasia: Holmium Laser Enucleation of the Prostate (HoLEP).
Published on: March 6, 2018
Benign prostatic hyperplasia: treat or wait?
John H Davidson1, Darryl S Chutka
1Division of General Internal Medicine, Mayo Clinic, Rochester, MN 55905, USA.
The Journal of Family Practice
|July 16, 2008
Summary
Men over 50 should discuss urinary function with their doctor. Evaluating symptoms and quality of life is key for managing benign prostatic hyperplasia (BPH) and choosing the best treatment.
Area of Science:
- Urology
- Men's Health
- Geriatric Medicine
Background:
- Lower urinary tract symptoms (LUTS) are common in men over 50.
- Benign prostatic hyperplasia (BPH) is a frequent cause of LUTS.
- Assessing patient-reported outcomes is crucial for effective management.
Purpose of the Study:
- To emphasize the importance of proactive screening for urinary dysfunction in men over 50.
- To guide healthcare providers in evaluating LUTS and BPH.
- To highlight the significance of quality of life in treatment decisions for BPH.
Main Methods:
- Routine communication with male patients aged 50+ regarding urinary function.
- Utilizing validated questionnaires like the International Prostate Symptom Score (IPSS).
- Conducting comprehensive medical histories, physical examinations (including DRE and neurological assessments), and laboratory tests to exclude other causes of LUTS.
Main Results:
- Systematic evaluation can identify and characterize urinary symptoms effectively.
- Quality of life (QoL) is a critical factor in patient-centered BPH management.
- Distinguishing BPH from other potential causes of LUTS is essential for appropriate treatment.
Conclusions:
- Open dialogue about urinary health is vital for older men.
- Patient-reported symptom severity and quality of life should guide BPH treatment.
- A thorough diagnostic approach ensures accurate diagnosis and tailored therapeutic strategies for LUTS.
Related Concept Videos
01:20Disorders of the Male Reproductive System
Men's health issues are increasingly recognized as significant, with several conditions posing common threats. Among these, testicular cancer is especially prevalent in younger men, particularly those aged 20 to 35 years. The disease often manifests as a painless mass in the testicles, sometimes accompanied by a sensation of heaviness or a dull ache.
Prostate disorders are another major concern. These conditions can impair urinary flow due to the prostate's location around the urethra. Symptoms...
Prostate disorders are another major concern. These conditions can impair urinary flow due to the prostate's location around the urethra. Symptoms...
01:28Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors
Phosphodiesterase 5 (PDE5) inhibitors are potent enzymes that function to hydrolyze cyclic nucleotides to their corresponding 5' monophosphates. Their unique biochemical properties have been applied in treating Pulmonary Arterial Hypertension (PAH).
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
01:30Urinary Tract Calculi III: Medical Management
The diagnosis of renal calculi involves several imaging techniques, including non-contrast CT scans and ultrasound. These methods help visualize kidney stones, assess their size and location, and detect possible obstructions. Additionally, Measuring urine pH is useful for diagnosing specific stone types, such as struvite (alkaline pH) and uric acid stones (acidic pH). Cystine stones are primarily linked to cystinuria, a genetic condition. A urinalysis helps detect blood in the urine (hematuria)...
01:23Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
01:30Urinary Tract Infection III: Diagnostic Studies and Interprofessional Care
A healthcare provider can diagnose a urinary tract infection (UTI) through several methods:Medical History and Symptoms: The provider will take a detailed medical history and ask about symptoms such as frequent urination, burning sensation during urination, and lower abdominal pain.Urinalysis: A clean-catch urine sample is collected in a sterile container and tested for the presence of bacteria, white blood cells (leukocytes), nitrites, blood, and protein. The presence of leukocytes and...
01:26Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers
Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...